



11-12-13 aprile 2024

Centro Congressi Lingotto, Torino

Thursday, 11th April, 2024

09.00 Registration
09.30 **OPENING SESSION**

Sala PARIGI
09.30-13.30

ECHO Course

- 09.30 Introduction and session presentation
- 10.00 Clinical Case from Torino, Mauriziano Hospital
- 10.20 Clinical Case from Novara
- 10.40 Clinical Case from Cuneo
- 11.00 Clinical Case from Vercelli
- 11.20 Clinical Case from Orbassano (TO)
- 11.40 Clinical Case from Rivoli (TO)
- 12.00 Clinical Case from Biella
- 12.20 Clinical Case from Torino, Maria Vittoria Hospital
- 12.40 Clinical Case from Torino, Città della Salute e della Scienza
- 13.00 LECTURE
- 13.30 Conclusions and take-home message

Sala BERLINO
09.30-13.30

ECG Course

- 09.15 CLINICAL CASE: Cuneo
- 09.35 CLINICAL CASE: Torino Ospedale Martini
- 09.55 CLINICAL CASE: Novi Ligure (AL)
- 10.15 CLINICAL CASE: Ciriè (TO)
- 10.35 CLINICAL CASE: Savigliano
- 10.55 CLINICAL CASE: Rivoli (TO)
- 11.15 CLINICAL CASE: Genova
- 11.35 CLINICAL CASE: Domodossola
- 11.55 CLINICAL CASE
- 12.15 Debate ECG interpretation: Human intelligence will stay
- 12.25 Debate ECG interpretation: AI will prevale
- 12.35 Discussion
- 13.00 Conclusions and take-home message
- 13.30 Session closure

ECHO
Course

ECHO

ECG
Course

ECG

09.00 Registration
09.30 **OPENING SESSION**

Sala MADRID

09.30-13.30

CHANGE COMPLEX CORONARY INTERVENTIONS AND CTO

09.45 **LIVE CASES**
from Rozzano, Milan and from al Qassimi Hospital, Dubai

CHANGE COMPLEX CORONARY INTERVENTIONS AND CTO: Clinical Experience

11.00 **LECTURE:** left main treatment: the latest evidences

11.10 **LIVE IN THE BOX** Complex PCI with IVAC 2L VENTRICULAR ASSIST DEVICE support

11.30 **LECTURE:** Imaging evaluation of vulnerable plaque

11.40 **LECTURE:** Functional guidance for complex PCI

11.50 Discussion

12.05 **LIVE CASES**
from Rozzano, Milan and from al Qassimi Hospital, Dubai

13.00 **LECTURE:** DCB technology: update and future direction

13.10 **LIVE IN THE BOX CTO PATIENT**

13.30 Closing Session

13.30-14.30 Lunch break

Sala MADRID

14.30-18.30

FROM DEVICES TO THERAPIES

14.30-16.00

CTO AND CHRONIC CORONARY SYNDROMES
Live background Rivoli and Genova

14.30 **LIVE** introduction from Rivoli and Genova
(the procedure will be displayed in the background)

14.45 **LECTURE:** What is my personal vision of a modern approach for CTO-PCI

15.00 Optimal anti-ischemic medical treatment in chronic coronary syndromes (CCS)

15.10 **LIVE IN THE BOX:** left main and bifurcation lesions with simulation lab

15.30 **LECTURE:** From Orbita to Ischemia trial: myths and realities in revascularization indications

15.40 Intravenous antiplatelet therapy in patients undergoing PCI: current prospective

15.50 **DISCUSSION** and **LIVE CASES** from Genova and Rivoli CTO procedure

16.00 Coffee break

16.20-18.00

ACUTE CORONARY SYNDROMES

16.20-17.00

MEDICAL AND INTERVENTIONAL TREATMENT IN COMPLEX CORONARY SETTINGS

16.20 Acute MI treatment in patients with multivessel disease: from PRAMI to MULTISTARS

16.30 Long-term antithrombotic treatment: the dual antiplatelet therapy vs dual pathway inhibition approach

16.40 Lipid lowering and dual pathway inhibition therapy in ACS patients with PAD

16.50 **CONCLUSIONS LIVE CORONARY INTERVENTION**
from Rivoli and Genova

17.00-18.00

LIPID-LOWERING AGENTS AND ANTITHROMBOTIC THERAPY IN THE ACUTE PHASE

17.00 Plaque stabilization and regression after ACS with I-PCSK9

17.10 The end of Stepwise approach: now is time of fast track

17.20 Current clinical practice in Lipid-lowering therapy Italy: the JET LDL Registry

17.30 Efficacy and safety of the PCSK9-I in the treatment of dyslipidemia in chronic kidney disease

17.40 How to deal with residual risk beyond LDL: the role of icosapent ethyl

17.50 Discussion

18.15 Closing session

Sala BERLINO

14.30-16.00

GENETIC IN CARDIAC DISEASES

CARDIOMYOPATHIES WITH HYPERTROPHIC PHENOTYPE

- 14.30 Genetic and clinical features on risk stratification and treatment of hypertrophic cardiomyopathy
- 14.40 Cardiac amyloidosis: contribution of genetic tests for diagnosis and therapy
- 14.50 Fabry disease: from genetic assessment to disease phenotype and treatment
- 15.00 Discussion

ARRHYTHMOGENIC CARDIOMYOPATHIES, BUT NOT ONLY...

- 15.15 Polygenic risk score in cardiovascular diseases
- 15.25 Arrhythmogenic ventricular cardiomyopathy: from genetic to phenotypic presentation
- 15.35 Brugada syndrome: from genetic to phenotypic presentation
- 15.45 Discussion

16.00 Coffee break

16.20-18.00

SPORT IN CARDIOLOGY

WHEN TO LOOK FOR ISCHEMIC OR VALVULAR CAUSES OF CARDIAC DISEASES IN THE ATHLETE

- 16.20 Coronary diseases and anomalies in the athlete
- 16.30 COCIS Guidelines on ischemic heart disease in the athlete
- 16.40 Valvular heart disease in the athlete
- 16.50 Discussion

NEWER EVIDENCE IN SPORT CARDIOLOGY

- 17.05 Collagenopathy and aortopathy in the athlete
- 17.15 Atrial fibrillation in the athlete: newer evidence
- 17.25 Master athlete and cardiac diseases: practical clinical recommendations
- 17.35 Discussion

Sala LONDRA

14.30-16.00

ARRHYTHMIAS AND HEART FAILURE

- 14.30 DISCUSSION and LIVE EP INTERVENTION FROM Novara and Rivoli
Bundle stimulation for physiological pacing - Novara
Electroporation Atrial Fibrillation Ablation - Rivoli
(the procedure will be displayed in the background)
- 14.45 Atrial ablation in heart failure: current prospective and future directions
- 14.55 Device therapy for heart failure management: what is the news?
- 15.05 Subcutaneous ICD: tips & tricks and pitfalls
- 15.15 Predicting and preventing sudden cardiac death in Brugada Syndrome
- 15.25 Ventricular arrhythmic storm interventional treatment

- 15.35 DISCUSSION and LIVE EP INTERVENTION FROM Novara and Rivoli
Bundle stimulation for physiological pacing - Novara
Electroporation Atrial Fibrillation Ablation - Rivoli
(the procedure will be displayed in the background)

16.00 Coffee break

16.20-17.00

ATRIAL FIBRILLATION UPDATE

- 16.20 Pulsed field ablation in Atrial Fibrillation
- 16.30 LAA closure update
- 16.40 How to choose appropriate direct oral anticoagulant for patient with atrial fibrillation
- 16.50 CONCLUSIONS LIVE EP INTERVENTION FROM Novara and Rivoli

17.00-18.00

THE CHALLENGES OF THE CARDIOLOGIST IN MANAGING THE HIGH-RISK PATIENTS

- 17.00 Who is the high-risk patient?
- 17.10 AF and Fragility: how to optimally treat AF patients with different risk factors?
- 17.20 New Oral Combination Therapy to meet LDL target
- 17.30 Clinical case: treatment planning in the management of high CV risk patient
- 17.45 Discussion
- 18.00 Closing session

AUDITORIUM Agnellii

08.15-13.40

LATEST FRONTIERS IN INTERVENTIONAL AND CLINICAL CARDIOLOGY

08.15-09.10 LIVE CASES FROM MASSA AND MAINZ

09.10-10.20

NEW HORIZONS IN TREATMENT OF CARDIOVASCULAR DISEASE

- 09.10 The SGLT2-I paradigm shift in clinical practice: how to optimize treatment in HFrEF and HFpEF
- 09.20 Intravenous antiplatelet therapy in patients undergoing PCI: why and when
- 09.30 Strike early and Strike Strong PCSK9-I in high risk patients
- 09.40 Management of Cardiovascular Disease in Patients with Obesity, Diabetes or both: Incretin-based therapies are the new tool in the toolbox
- 09.50 Discussion

10.10 Coffee break

10.30-11.30 LIVE CASES FROM MASSA AND MAINZ

11.30-12.30

THE MASTER LECTURES

- 11.30 The mystery and magic of the vulnerable atherosclerotic plaque
- 11.40 The emergence of computational interventional physiology: how AI reveals all the content that is hidden in the simple angiogram
- 11.50 Update of ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: how to apply them in practice
- 12.00 Fast track use of I-PCSK9: the lesson of AT TARGET-IT
- 12.10 The fifth cardiac chamber

12.30-13.30

BURNING DEBATES

BURNING DEBATE 1: Don't stop me now? TAVI age & indications

- 12.30 Age is the real gate-keeper
- 12.37 Age is not a barrier
- 12.44 Discussion and vote

BURNING DEBATE 2: Solving the mystery of coronary perfusion

- 12.50 Invasive strategy
- 12.57 Nuclear non invasive strategy
- 13.04 Discussion and vote
- 13.10 Discussion

13.20-14.00

OPENING CEREMONY

14.00-15.00
Lunch break

Sala LONDRA

15.00-16.00 LIVE CASES FROM MAURIZIANO AND NOVARA HOSPITAL TAVI

16.00 Coffee break

16.30-17.00

THE MASTER LECTURES

- 16.30 Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy
- 16.40 The role of 3D in clinical practice
- 16.50 MINOCA from diagnosis to treatment

17.00-18.00

CLINICAL COMPETENCE IN ICCU: ACUTE HEART FAILURE-STATE OF THE ART 2024

- 17.00 Optimal medical management: contemporary role of IV vasodilators and inotropes
- 17.10 Evaluation and treatment of congestion before discharge
- 17.20 Percutaneous Mechanical Circulatory Support in Cardiogenic Shock
- 17.30 How to deal with a patient with fever in the ICU
- 17.40 Discussion

18.00-18.45

PHYSIOLOGY AND INTRAVASCULAR IMAGING

- 18.00 LECTURE: OCT evaluation of high risk plaques
- 18.10 LECTURE: Coronary physiology to guide complete revascularization in patients with AC: lessons from FIRE Trial
- 18.20 Clinical Case: Maximal hyperemia FFR and imaging
- 18.30 OCT to guide and optimize PCI of complex coronary bifurcation lesions from OCTOBER Trial
- 18.40 Discussion
- 18.50 Closing session

Sala BERLINO

15.00-16.00

LIPID-LOWERING COMBINATION THERAPY TO REDUCE CARDIOVASCULAR EVENTS

- 15.00 Combination therapy high-intensity statin, ezetimibe should be the first line treatment in very high-risk patients
- 15.10 Learn about an siRNA-based LDL-C-lowering therapy
- 15.20 The new oral add-on option for lowering LDL in high and very high risk patient
- 15.30 Can we eradicate atherosclerosis? New targets and new drugs
- 15.40 Discussion

16.00 Coffee break

16.20-16.50

DIABETES AND CARDIOVASCULAR DISEASE

- 16.20 Clinical Scenario: Diabetic patients with ACS treated with PCI
- 16.25 EXPERT: GLP-1 receptor agonist in diabetic patients with history of acute coronary syndrome
- 16.35 Scenario's Solution
- 16.40 Discussion

16.50- 17.20

OBESITY AND CARDIOVASCULAR DISEASE

- 16.50 Clinical Scenario: Obesity in high risk patient
- 16.55 Managing HFpEF as a Cardiometabolic Disease: Current State and Future Directions
- 17.05 Scenario's Solution
- 17.10 Discussion

17.20- 18.15

VASCULAR ATHEROTHROMBOTIC DISEASE: A MULTIDISCIPLINAR APPROACH

- 17.20 Surgical and endovascular option for TAA
- 17.30 Endovascular treatment for extracranial carotid artery disease
- 17.40 Lipid lowering therapy optimization in PAD
- 17.50 Network cardiologist and vascular surgeon: the Match-PAD Registry
- 18.00 Discussion

18.15-18.45

HYPOLIPIDEMIC STRATEGY IN PATIENTS WITH MULTIPLE CV EVENTS

- 18.15 Clinical Scenario: patient with recurrent elective PCI
- 18.20 PCSK9-I in patient with multiple CV events: is one-month administration the better solution?
- 18.30 Scenario's Solution
- 18.35 Discussion
- 18.45 Closing session

Sala MADRID

15.00-16.00

STRUCTURAL HEART INTERVENTIONS: Not only TAVI

15.00-16.00 LIVE INTERVENTION FROM RIVOLI AND GENOVA

16.00 Coffee break

16.30-17.10

THE ROLE OF NEW PARENTERAL ANTIPLATELET THERAPY

- 16.30 Clinical Scenario: STEMI undergoing primary PCI
- 16.40 Clinical Scenario: NSTEMI without oral pre-treatment
- 16.50 Differences across European practices for peri-PCI antiplatelet management for NSTE-ACS patient: the READAPT medical survey results
- 17.00 Discussion with Experts

17.10-17.40

MITRAL AND ECHO

- 17.10 EXPERT: Edge-to-edge mitral repair update
- 17.20 LECTURE: Echocardiography guidance of Mitral and LAA intervention
- 17.30 Discussion

17.40-18.45

A FULL-SPECTRUM VIEW OF CARDIOVASCULAR DISEASE

- 17.40 Sex-based differences in risk factors for incident myocardial infarction and stroke
- 17.50 Takotsubo syndrome: new diagnostic features and future therapeutic perspectives
- 18.00 Heart failure second line therapy
- 18.10 Myocardial perfusion by means of PET Rubidio scan
- 18.20 INOCA from diagnosis to treatment
- 18.30 Discussion
- 18.45 Session closure

Sala PARIGI

15.00-16.00

NEWEST PHARMACOLOGIC AGENTS IN THE TREATMENT OF HEART FAILURE AND ATRIAL FIBRILLATION

- 15.00 Direct oral anticoagulants in frail patients
- 15.10 SGLT2 inhibitors across the broad spectrum of Ejection fraction
- 15.20 PredischARGE therapy in HFREF patient. Which is the priority on top of BB? Arni or SGLT2i

- 15.30 Vericiguat in heart failure: from scientific evidence to clinical practice
- 15.40 DOACs in patients with CKD
- 15.50 Discussion

16.10 Coffee break

16.30-17.30

NEW LIPID-LOWERING AGENTS IN ALL SPECTRUM RISK PATIENTS

- 16.30 New Lipid-lowering agents: my clinical practice to improve adherence and persistence with SirNA
- 16.40 CLINICAL CASE: Very high risk patient with chronic coronary syndrome
- 16.50 CLINICAL CASE: application of Fast-track reimbursement in patient with acute coronary syndrome
- 17.00 CLINICAL CASE: application of Fast-track reimbursement in patient with multiple cardiovascular events
- 17.10 Discussion

17.30-18.30

BEST CLINICAL CASE AND ABSTRACTS

Sala BERLINO

09.00-14.00

PRACTICAL CLINICAL THEATERS IN CARDIOLOGY
OF THE PRESENT AND THE FUTURE

09.00-14.00

CORONARY INTERVENTION. SHARE YOUR EXPERIENCE!

- 09.00 PCI for complex Left main disease: The Rolex lesson
- 09.10 CLINICAL CASE: New generation bioabsorbable Scaffold coronary stent
- 09.30 CLINICAL CASE: Intravascular lithotripsy for severe calcific coronary lesions
- 09.50 CLINICAL CASE: DCB in diffuse coronary disease
- 10.10 CLINICAL CASE: Cutting balloon for severe and diffuse coronary calcifications
- 10.30 CLINICAL CASE: PCSK9 inhibitors at discharge in ACS: a JET LDL patient
- 10.50 Functional evaluation in PCI: when, where and how

11.00 Coffee break

- 11.30 Modern approach to bifurcation lesions
- 11.40 CLINICAL CASE: A Challenging coronary bifurcation
- 12.00 Imaging evaluation in PCI: when, where and how
- 12.10 CLINICAL CASE: OCT-guided PCI
- 12.30 CLINICAL CASE: Functional guidance for PCI
- 12.50 Renal Denervation: the new era of the hypertension treatment
- 13.00 CLINICAL CASE: Renal denervation with second generation device
- 13.20 Discussion and Conclusions
- 14.00 Final thanks and event conclusion

Sala MADRID

09.00-14.00

STRUCTURAL INTERVENTION. SHARE YOUR EXPERIENCE!

- 09.00 CLINICAL CASE: Edge to Edge mitral valve repair: the PASCAL system
- 09.20 CLINICAL CASE: G4 Edge to edge repair: multiple sizes for a tailored approach
- 09.40 CLINICAL CASE: Tricuspid valve repair
- 10.00 LECTURE: LAA occluder for stroke prevention
- 10.10 PFO update: how to choose the correct device and strategy

- 10.20 CLINICAL CASE: Mechanical thrombectomy in pulmonary embolism
- 10.40 CLINICAL CASE: Valve in Valve and aortic aneurism: how I solved the issue

11.00 Coffee break

- 11.30 TRACS program update
- 11.40 TAVI at home program update
- 11.50 CLINICAL CASE:How a new TAVI platform deals with hostile accesses
- 12.10 CLINICAL CASE: Balloon-expandable TAVR in severe bicuspid aortic stenosis
- 12.30 CLINICAL CASE: Top-down self-apposing TAVR deployment
- 12.50 CLINICAL CASE: Self-apposing TAVR in horizontal aorta
- 13.10 CLINICAL CASE: Novel self-expandable supra-annular TAVR
- 13.30 Discussion and Conclusions
- 14.00 Final thanks and event conclusion

Sala LONDRA

09.00-14.00

ARRHYTHMIAS AND CARDIAC RHYTHM MANAGEMENT.
SHARE YOUR EXPERIENCE!

09.00 LIVE EP INTERVENTION FROM Maurizioano and NOVARA HOSPITAL

Flash debate: IBBP-CRT or BiVP-CRT in patients
with heart failure and reduced left ventricular ejection fraction?

- 10.10 LBBB-CRT
- 10.20 BiVP-CRT
- 10.30 Discussion
- 10.40 CLINICAL CASE: The subcutaneous implantable cardioverter-defibrillator repositioning

11.00 Coffee break

- 11.30 CLINICAL CASE: AF ablation
- 11.50 CLINICAL CASE: CRT
- 12.10 CLINICAL CASE: Cryoablation
- 12.30 CLINICAL CASE: The AV Leadless pacemaker
- 12.50 CLINICAL CASE: the role of the wearable cardioverted defibrillator
- 13.10 Discussion
- 13.40 Conclusions
- 14.00 Final thanks and event conclusion